Zacks Research Equities Analysts Cut Earnings Estimates for Amarin Co. plc (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN) – Stock analysts at Zacks Research reduced their Q3 2025 earnings estimates for Amarin in a research report issued on Wednesday, June 26th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($0.06) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Amarin’s current full-year earnings is ($0.18) per share. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.24) EPS and FY2026 earnings at ($0.14) EPS.

Amarin (NASDAQ:AMRN) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $56.52 million during the quarter, compared to analysts’ expectations of $51.34 million. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. During the same period in the previous year, the company earned ($0.04) earnings per share.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research note on Tuesday, June 18th. StockNews.com cut shares of Amarin from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $1.08.

Amarin Stock Up 2.8 %

NASDAQ AMRN opened at $0.71 on Monday. The stock has a market capitalization of $289.52 million, a PE ratio of -5.88 and a beta of 1.95. The company has a 50 day moving average price of $0.81 and a two-hundred day moving average price of $0.95. Amarin has a 12-month low of $0.63 and a 12-month high of $1.49.

Hedge Funds Weigh In On Amarin

Large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP increased its holdings in Amarin by 74.4% in the 1st quarter. GSA Capital Partners LLP now owns 1,482,540 shares of the biopharmaceutical company’s stock valued at $1,321,000 after buying an additional 632,497 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Amarin by 104.8% in the 1st quarter. BNP Paribas Financial Markets now owns 932,173 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 476,996 shares during the last quarter. Simplicity Wealth LLC bought a new stake in shares of Amarin in the 1st quarter worth about $418,000. Hayek Kallen Investment Management grew its holdings in shares of Amarin by 63.3% in the 4th quarter. Hayek Kallen Investment Management now owns 1,016,760 shares of the biopharmaceutical company’s stock worth $885,000 after purchasing an additional 394,117 shares during the last quarter. Finally, Gilliland Jeter Wealth Management LLC bought a new stake in shares of Amarin in the 4th quarter worth about $64,000. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.